Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Hansa Biopharma – Presentation of Half-Year Report 2023

By HC Andersen Capital
Hansa Biopharma

Meet and ask questions to Head of IR Klaus Sindahl from Hansa Biopharma Thursday the 20th of July at 11 AM CEST when he presents the Half-Year report and the latest development in the pipeline.

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving, and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy, and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA.

Disclaimer: HC Andersen Capital receives payment from Hansa Biopharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 09.59AM on 21/06-2023.

Recent videos

Rapala H2'25: North American sales a highlight of the end of the year
12.03.2026 klo 17.25 Rapala VMC
Columbus – Presentation of Annual Report 2025
12.03.2026 klo 14.00 Columbus
Tokmanni Q4’25: Dollarstore’s turnaround is stalling
12.03.2026 klo 13.02 Tokmanni Group
Multitude, Webcast, Q4'25
12.03.2026 klo 11.00 Multitude
Rapala VMC Oyj, Audiocast, Q4'25
12.03.2026 klo 11.00 Rapala VMC
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.